3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Interventions
pembrolizumab
2
romidepsin
1
montanide ISA 51
1
brostallicin
1
belinostat
1
Trabectedin
1
Sunitinib
1
Ritonavir
1
Radiotherapy
1
Ipilimumab
1
Interleukin-2
1
Indinavir
1
Imatinib Mesylate
1
Histamine H2 Antagonists
1
HhAntag691
1
Fluorouracil
1
Famotidine
1
Angptl4 protein, mouse
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Famotidine
×
Gastrointestinal
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled